Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
7 participants
INTERVENTIONAL
2001-09-30
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
NCT00419146
Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia
NCT00585390
Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis
NCT00396643
Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia
NCT02210962
Omega-3 Dietary Supplements in Schizophrenia
NCT01786239
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ethyl-eicosapentaenoic acid
2 mg per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ethyl-eicosapentaenoic acid
2 mg per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
14 Years
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yale University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott W Woods, MD
Role: PRINCIPAL_INVESTIGATOR
Yale University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LA01.03.0011
Identifier Type: -
Identifier Source: org_study_id
NCT00237835
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.